Li Yan, Castellano Joan J, Moreno Isabel, Martínez-Rodenas Francisco, Hernandez Raquel, Canals Jordi, Diaz Tania, Han Bing, Muñoz Carmen, Biete Albert, Monzo Mariano, Navarro Alfons
Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, Faculty of Medicine and Health Sciences, University of Barcelona, IDIBAPS, 08036 Barcelona, Spain.
Department of Medical Oncology and Surgery, Hospital Municipal de Badalona, 08911 Badalona, Spain.
Life (Basel). 2020 Aug 31;10(9):172. doi: 10.3390/life10090172.
LincRNA-p21 is a long non-coding RNA involved in the p53 pathway and angiogenesis regulation that acts as prognostic marker in several tumors. In the present study, we aimed to analyze the clinical value of lincRNA-p21 in 177 resected stage I-III colorectal cancer (CRC) patients. Tumor and normal paired tissue and plasma samples from tumor-draining mesenteric veins and paired peripheral veins were analyzed. LincRNA-p21 expression was determined by RTqPCR and correlated with disease-free (DFS) and overall survival (OS). LincRNA-p21 was downregulated in tumor versus normal tissue ( = 0.0012). CRC patients with high lincRNA-p21 expression had shorter DFS ( = 0.0372) and shorter OS ( = 0.0465). Of note, the major prognostic impact was observed in the subset of rectal cancer patients where patients with high lincRNA-p21 levels had worse DFS ( = 0.0226) and OS ( = 0.0457). Interestingly, rectal cancer patients with high lincRNA-p21 benefited from post-operative chemoradiotherapy, as indicated by a longer OS in the group of high lincRNA-p21 patients receiving post-operative chemoradiotherapy ( = 0.04). Finally, patients with high lincRNA-p21 levels in mesenteric vein (MV) had shorter OS ( = 0.0329). LincRNA-p21 is a marker of advanced disease and worse outcome in CRC. Moreover, rectal cancer patients with high lincRNA-p21 levels could benefit from post-operative chemoradiotherapy, and plasmatic-lincRNA-p21 is a promising liquid biopsy biomarker.
LincRNA-p21是一种长链非编码RNA，参与p53通路和血管生成调节，在多种肿瘤中作为预后标志物。在本研究中，我们旨在分析lincRNA-p21在177例I-III期切除的结直肠癌（CRC）患者中的临床价值。分析了肿瘤与正常配对组织以及来自肿瘤引流肠系膜静脉和配对外周静脉的血浆样本。通过RTqPCR测定LincRNA-p21表达，并将其与无病生存期（DFS）和总生存期（OS）相关联。与正常组织相比，肿瘤组织中LincRNA-p21表达下调（P = 0.0012）。LincRNA-p21高表达的CRC患者DFS较短（P = 0.0372），OS也较短（P = 0.0465）。值得注意的是，在直肠癌患者亚组中观察到主要的预后影响，其中LincRNA-p21水平高的患者DFS较差（P = 0.0226），OS也较差（P = 0.0457）。有趣的是，LincRNA-p21高表达的直肠癌患者从术后放化疗中获益，如接受术后放化疗的LincRNA-p21高表达患者组的OS较长所示（P = 0.04）。最后，肠系膜静脉（MV）中LincRNA-p21水平高的患者OS较短（P = 0.0329）。LincRNA-p21是CRC中晚期疾病和较差预后的标志物。此外，LincRNA-p21水平高的直肠癌患者可从术后放化疗中获益，血浆LincRNA-p21是一种有前景的液体活检生物标志物。
